BRIEF-Santhera Pharmaceuticals: CHF 49.8 mln in cash and cash equivalents by end of 2016

* Reports FY net revenues of 19.0 million Swiss francs

($19.02 million)(+340% year-on-year) from sales of its lead

product Raxone for treatment of leber's hereditary optic

neuropathy (LHON)

Read more